Xevudy is a medicine used for treating COVID-19 in adults and adolescents (from 12 years of age and weighing at least 40 kilograms) who do not require supplemental oxygen and who are at increased risk of the disease becoming severe. Xevudy contains the active substance sotrovimab.
Therapeutic Indication
### Therapeutic indication Xevudy is indicated for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (COVID-19) who do not require oxygen supplementation and who are at increased risk of progressing to severe COVID-19.
Therapeutic Area (MeSH)
ATC Code
J06BD05
ATC Item
sotrovimab
Pharmacotherapeutic Group
Immune sera and immunoglobulins
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| sotrovimab | N/A | Sotrovimab |
| Sotrovimab | N/A | Sotrovimab |
EMA Name
Xevudy
Medicine Name
Xevudy
Aliases
N/ANo risk management plan link.
